Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

NSOLIDATED STATEMENTS OF OPERATIONS Three months ended Six months ended June 30, June 30, ------------------ ------------------ 2009 2008 2009 2008 ---- ---- ---- ---- (Unaudited) (Unaudited) Revenue: Collaboration revenue-related party $1,500,000 $2,544,868 $1,500,000 $4,310,551 Collaboration revenue-other 12,500 46,372 25,000 583,872 License and other revenue 2,000,000 - 2,211,547 - --------- --------- --------- --------- Total revenues 3,512,500 2,591,240 3,736,547 4,894,423 Operating expenses: Research and development 3,448,685 8,262,604 7,712,836 17,005,499 General and administrative 1,994,903 3,235,061 4,349,916 6,501,190 Restructuring charges 532 4,876,746 1,863,393 5,197,520 --------- --------- --------- --------- Total operating expenses 5,444,120 16,374,411 13,926,145 28,704,209 --------- ---------- ---------- ---------- Loss from operations (1,931,620) (13,783,171) (10,189,598) (23,809,786) Interest income 6,000 269,385 18,812 729,797 Interest expense (375) (54,433) (987) (113,806) Other income (expense), net (20,952,469) (199) (21,070,126) 472 ----------- ----------- ----------- ------
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... , May 1, 2015 ... Production Market by Product (Equipment, Consumables), by Type (Monoclonal, ... Diagnostic Labs, Research Institutes) - Analysis & Global ... studies the global Antibody Production Market for the ... is expected to reach $2.572 Billion by 2019 ...
(Date:4/30/2015)... CA (PRWEB) April 30, 2015 Cytokinetics, Incorporated ... first quarter of 2015 were $4.4 million, compared to $8.0 ... loss for the first quarter was $8.9 million, or $0.23 ... net loss for the same period in 2014, of $8.7 ... of March 31, 2015, cash, cash equivalents and investments totaled ...
(Date:4/30/2015)... Budapest, Hungary (PRWEB) April 30, 2015 ... electronic lab notebook with integrated protocols and specimen ... chemistry software solutions and consulting services for life ... the development of Labguru’s newest feature: chemical structure ... deep domain features for biologists, bio-chemists, and more, ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... , , MONTREAL , Jan. ... successful completion of a dose-ranging Phase 1 study and the ... combination with sorafenib for the treatment of patients with advanced ... "A Phase 2, Open-Label Study of The X-Linked Inhibitor of ...
... , , SHANGHAI ... Ltd., a,leading pharmaceutical R&D outsourcing Service Company in China ... Minster Jean-Pierre,Raffarin visited Sundia on January 22, 2010 . ... by Dr. Serge,Feneuille and Mr. Erwan Davoux ...
... LEIDEN, The Netherlands , January 26 ... are extremely,valuable for pharmaceutical research in the Netherlands . ... Top Institute, which was published today. In,the report, an independent ... is well on its way to achieving the objectives that ...
Cached Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma 2Former French Prime Minister Jean-Pierre Raffarin Visits Sundia 2Veerman Committee Argues for Continuation of TI Pharma 2
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... is also available in Spanish . , ... levels becomes accustomed to the presence of an exogenous surplus, ... source--in this case, alcohol. , According to a study by ... the University of Granada , although there are no ...
... 2007 UT Southwestern Medical Center researchers have found that ... excludes a group of obese patients at risk of cardiovascular ... of the journal Surgery for Obesity and Related Diseases, ... between body mass index (BMI) and cardiovascular disease as it ...
... to induce cells to form parallel tube-like structures that could ... researchers found that they can control the cells, development by ... on the work was posted this month in an online ... one day be transplanted into tissues such as the kidneys, ...
Cached Biology News:A research of the UGR shows the genetic predisposition to develop alcohol abuse 2BMI criteria for obesity surgery should be lowered, UT Southwestern researcher suggests 2MIT works toward engineered blood vessels 2
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
Mouse Anti-Human MCAF-(MCP-1)...
Biology Products: